Janus Capital's Bill Gross: have been selling Bunds; short Italy and mildly short US Treasuries - TV interview
- The US economy is running hot because of the deficit and tax cuts
Gapping down
In reaction to disappointing earnings/guidance:
- LMAT -16.6% (reports prelim Q3 sales below consensus and downside Q4 guidance), CUTR -16.3% (guides Q3 below consensus, lowers FY18 revenue outlook), COST -2.5% (also expects to report a material weakness in internal in its upcoming fiscal 2018 Annual Report on Form 10-K)
Other news:
- IGC -21.5% (extending yesterday's pull back)
- TSLA -3.3% (continued weakness as Elon Musk comments on SEC)
- AZRE -2.8% (prices 14.8 mln equity share offering at $12.50/share)
- AZUL -1.2% (preliminary traffic results for September)
Analyst comments:
- HPQ -2.1% (downgraded to Neutral from Overweight at JP Morgan)
- EMN -1.6% (downgraded to Neutral from Overweight at JP Morgan)
- MYL -1.2% (downgraded to Neutral from Buy at Mizuho)
- COMM -1.1% (downgraded to Neutral from Buy at Nomura)
- HCLP -0.8% (downgraded to Neutral at UBS)
![]()
Gapping up
In reaction to strong earnings/guidance:
- SGH +14.5%, EMKR +13.8% (raises Q4 revenue guidance), HIMX +5.9% (Q3 guidance)
M&A news:
- PDS +0.9% (to acquire all shares of Trinidad Drilling in deal worth $1.028 bln)
Other news:
- GPRO +6.9% (announces that HERO7 Black has achieved the highest week-one retail unit sell-thru of any new camera in the company's history)
- PXLW +6.5% (after announcing the new Nokia 7.1 smartphone incorporates Pixelworks' latest Iris PX8418 mobile processing chip)
- NBEV +6% (preparing CBD-infused beverage launch with pre-order discussions, according to Bloomberg)
- AKCA +4.9% (Akcea Therapeutics and Ionis Pharmaceuticals (IONS) announce that TEGSEDI has been approved in Canada)
- TLRY +4.7% (prices an upsized offering of $450 mln aggregate principal amount of Convertible Senior Notes due 2023)
- SNAP +4.5% (reports that CEO Evan Spiegel emailed employees outlining priorities, discussed flaws of 'rushed redesign', and established goal of profitability in 2019)
- MNOV +4.4% (confirms being granted FDA orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma)
- VSTM +3.8% (indicated higher following the publication of the Phase 3 DUO study results evaluating COPIKTRA in peer-reviewed journal Blood)
- PRTK +3.4% (announces acceptance of European Marketing Authorization application for oral and intravenous omadacycline)
- FOLD +3.1% (announces positive 18-month data in Pompe disease phase 1/2 study)
Analyst comments:
- BJRI +2% (upgraded to Overweight from Neutral at Piper Jaffray)
- LLY +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- QNST +0.6% (initiated with Outperform at William Blair)
![]()
Gapping up:
- SGH +15.4%, EMKR +9.8%, GPRO +7.8%, PXLW +6.5%, AKCA +4.9%, TLRY +4.6%, MNOV +4.4%, VSTM +4.3%, HIMX +3.6%, PRTK +2.8%, PTEN +1.1%, PDS +0.9%, IONS +0.7%, QNST +0.6%
Gapping down:
- IGC -17.3%, LMAT -16.6%, CUTR -16.3%, TSLA -2.8%, COST -2.4%, PENN -0.7%, LUV -0.7%, FTNT -0.6%
![]()